Clinical Trial Update: A Safety and Immunogenicity Trial With an Adjuvanted TB Subunit Vaccine (Ag85B-ESAT-6 + IC31) [Phase 1]

View source ↗

Summary

Phase 1 safety and immunogenicity results for an adjuvanted tuberculosis subunit vaccine (Ag85B-ESAT-6 with IC31) have been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• Ag85B-ESAT-6 + IC31 TB Subunit Vaccine (Ag85B-ESAT-6 subunit vaccine adjuvanted with IC31)

Snippet

Sponsor: Statens Serum Institut | Conditions: Tuberculosis | Phase 1 | Status: COMPLETED